[go: up one dir, main page]

GB9511935D0 - Novel compound - Google Patents

Novel compound

Info

Publication number
GB9511935D0
GB9511935D0 GBGB9511935.0A GB9511935A GB9511935D0 GB 9511935 D0 GB9511935 D0 GB 9511935D0 GB 9511935 A GB9511935 A GB 9511935A GB 9511935 D0 GB9511935 D0 GB 9511935D0
Authority
GB
United Kingdom
Prior art keywords
novel compound
novel
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GBGB9511935.0A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Priority to GBGB9511935.0A priority Critical patent/GB9511935D0/en
Publication of GB9511935D0 publication Critical patent/GB9511935D0/en
Priority to EP96917584A priority patent/EP0832219A2/en
Priority to CA002224646A priority patent/CA2224646A1/en
Priority to PCT/GB1996/001388 priority patent/WO1997000319A2/en
Priority to JP9502784A priority patent/JPH11507547A/en
Priority to AU60110/96A priority patent/AU6011096A/en
Priority to US09/859,361 priority patent/US20020058311A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Child & Adolescent Psychology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
GBGB9511935.0A 1995-06-13 1995-06-13 Novel compound Pending GB9511935D0 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
GBGB9511935.0A GB9511935D0 (en) 1995-06-13 1995-06-13 Novel compound
EP96917584A EP0832219A2 (en) 1995-06-13 1996-06-11 Chimeric leptin fused to immunoglobulin domain and use
CA002224646A CA2224646A1 (en) 1995-06-13 1996-06-11 Chimeric leptin fused to immunoglobulin domain and use
PCT/GB1996/001388 WO1997000319A2 (en) 1995-06-13 1996-06-11 Chimeric leptin fused to immunoglobulin domain and use
JP9502784A JPH11507547A (en) 1995-06-13 1996-06-11 Chimeric leptin fused with immunoglobulin domain and uses thereof
AU60110/96A AU6011096A (en) 1995-06-13 1996-06-11 Chimeric leptin fused to immunoglobulin domain and use
US09/859,361 US20020058311A1 (en) 1995-06-13 2001-05-17 Chimeric leptin fused to immunoglobulin domain and use

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9511935.0A GB9511935D0 (en) 1995-06-13 1995-06-13 Novel compound

Publications (1)

Publication Number Publication Date
GB9511935D0 true GB9511935D0 (en) 1995-08-09

Family

ID=10775951

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9511935.0A Pending GB9511935D0 (en) 1995-06-13 1995-06-13 Novel compound

Country Status (6)

Country Link
EP (1) EP0832219A2 (en)
JP (1) JPH11507547A (en)
AU (1) AU6011096A (en)
CA (1) CA2224646A1 (en)
GB (1) GB9511935D0 (en)
WO (1) WO1997000319A2 (en)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6310034B1 (en) 1993-05-21 2001-10-30 Ut-Battelle, Llc Agouti polypeptide compositions
US6001968A (en) * 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
DE69638119D1 (en) * 1995-11-22 2010-03-11 Amgen Inc Method of increasing lean meat mass with obesity protein (OB) compositions
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
IL124831A0 (en) * 1995-12-27 1999-01-26 Genentech Inc Ob protein derivatives having prolonged half-life
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
AU769250B2 (en) * 1995-12-27 2004-01-22 Genentech Inc. OB protein derivatives having prolonged half-life
US7074397B1 (en) 1996-01-08 2006-07-11 Genentech, Inc. Method for enhancing proliferation or differentiation of a cell using ob protein
US6541604B1 (en) 1996-01-08 2003-04-01 Genentech, Inc. Leptin receptor having a WSX motif
US20050019325A1 (en) 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
AU770897B2 (en) * 1996-12-20 2004-03-04 Amgen, Inc. OB fusion protein compositions and methods
EA004790B1 (en) * 1996-12-20 2004-08-26 Амген Инк. Ob fusion protein compositions and methods
AU6656098A (en) * 1997-02-25 1998-09-09 Eli Lilly And Company Treatment of infertility with leptin receptor ligands
ES2183351T3 (en) * 1997-04-17 2003-03-16 Amgen Inc COMPOSITIONS THAT INCLUDE CONJUGATES OF STABLE ACTIVE HUMAN PROTEIN WITH AN FC CHAIN OF IMMUNOGLOBULINS AND METHODS.
US20020019352A1 (en) * 1997-04-17 2002-02-14 David N. Brems Stable, active, human ob protein compositions and methods
AU2002300605B8 (en) * 1997-04-17 2006-02-09 Amgen Inc. Compositions Comprising Conjugates of Stable, Active, Human OB Protein with Antibody FC Chain and Methods
US6187564B1 (en) 1997-07-10 2001-02-13 Beth Israel Deaconess Medical Center DNA encoding erythropoietin multimers having modified 5′ and 3′ sequences and its use to prepare EPO therapeutics
US6242570B1 (en) 1997-07-10 2001-06-05 Beth Israel Deaconess Medical Center Production and use of recombinant protein multimers with increased biological activity
US6165476A (en) * 1997-07-10 2000-12-26 Beth Israel Deaconess Medical Center Fusion proteins with an immunoglobulin hinge region linker
AU8182298A (en) * 1997-07-10 1999-02-08 Beth Israel Deaconess Medical Center Recombinant erythropoietin / immunoglobulin fusion proteins
DK1037927T3 (en) 1997-12-08 2004-09-06 Emd Lexigen Res Ct Corp Heterodimeric fusion proteins useful for targeted immunotherapy and general immune stimulation
CZ20003099A3 (en) * 1998-02-25 2002-04-17 Lexigen Pharmaceuticals Corporation Enhancing the circulating half-life of antibody-based fusion proteins
CA2335107C (en) 1998-07-28 2010-01-19 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Leptin-mediated gene-induction
SK9432001A3 (en) * 1999-01-07 2003-02-04 Lexigen Pharm Corp Expression and export of anti-obesity proteins as Fc fusion proteins
AU766507B2 (en) * 1999-05-07 2003-10-16 Genentech Inc. Novel chimpanzee erythropoietin (CHEPO) polypeptides and nucleic acids encoding the same
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
PL202058B1 (en) 1999-08-09 2009-05-29 Merck Patent Gmbh Multiple cytokine−antibody complexes
AU7699900A (en) * 1999-10-01 2001-05-10 Eli Lilly And Company A novel human leptin homolog
JP2003514552A (en) 1999-11-12 2003-04-22 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング Erythropoietin morphology with improved properties
DE60122286T2 (en) * 2000-02-11 2007-08-02 Merck Patent Gmbh INCREASING THE CIRCULATORY HALF-TIME OF ANTIBODY-BASED FUSION PROTEINS
EP1283878B1 (en) 2000-05-22 2005-07-27 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Receptor-based interaction trap
ES2288967T3 (en) 2000-06-29 2008-02-01 Merck Patent Gmbh REINFORCEMENT OF IMMUNE ANSWERS MEDIATED BY THE ANTIBODY-CYTOKIN FUSION PROTEIN THROUGH THE TREATMENT COMBINED BY AGENTS THAT IMPROVE THE INCORPORATION OF IMMUNOCITOQUINE.
US7235629B2 (en) 2000-11-14 2007-06-26 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Functional fragment of the leptin receptor
MXPA03007323A (en) * 2001-02-19 2003-12-12 Merck Patent Gmbh Artificial proteins with reduced immunogenicity.
BR0207854A (en) 2001-03-07 2004-08-24 Merck Patent Gmbh Expression technology for proteins containing a hybrid isotype antibody moiety
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
HUP0400284A3 (en) 2001-05-03 2012-09-28 Merck Patent Gmbh Recombinant tumor specific antibody and use thereof
US7737260B2 (en) 2003-11-13 2010-06-15 Hanmi Pharm. Co., Ltd Protein complex using an immunoglobulin fragment and method for the preparation thereof
PL206975B1 (en) 2001-12-04 2010-10-29 Merck Patent Gmbh Immunocytokines with modulated selectivity
RU2366664C2 (en) 2002-12-17 2009-09-10 Мерк Патент Гмбх Humanised antibody (h14,18) based on mouse antibody 14,18, contacting gd2, and its fusion with il-2
US20070253966A1 (en) * 2003-06-12 2007-11-01 Eli Lilly And Company Fusion Proteins
ATE525395T1 (en) 2003-06-12 2011-10-15 Lilly Co Eli FUSION PROTEINS OF GLP-1 ANALOGS
EP1673395A1 (en) 2003-10-15 2006-06-28 PDL BioPharma, Inc. Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
BRPI0418286A (en) 2003-12-30 2007-05-02 Merck Patent Gmbh il-7 fusion proteins
CA2551916C (en) 2003-12-31 2014-04-29 Merck Patent Gesellschaft Mit Beschraenkter Haftung Fc-erythropoietin fusion protein with improved pharmacokinetics
EP1702069A2 (en) 2004-01-05 2006-09-20 EMD Lexigen Research Center Corp. Interleukin-12 targeted to oncofoetal fibronectin
US7423113B2 (en) 2004-08-25 2008-09-09 Vib Vzw Leptin antagonist
WO2006053883A1 (en) 2004-11-18 2006-05-26 Vib Vzw Fibronectin iii domain as leptin receptor antagonists
RU2437893C2 (en) 2004-12-09 2011-12-27 Мерк Патент Гмбх Il-7 versions with low immunising capacity
ATE435235T1 (en) * 2004-12-22 2009-07-15 Lilly Co Eli FORMULATIONS OF GLP-1 ANALOGUE FUSION PROTEINS
CA2640066A1 (en) * 2006-01-24 2007-08-02 Roland Beckmann Fusion proteins that contain natural junctions
EA201171259A1 (en) 2009-04-22 2012-05-30 Мерк Патент Гмбх ANTIBODY HYBRID PROTEINS WITH MODIFIED FCRN BINDING SITES

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59109269D1 (en) * 1990-06-28 2005-12-15 Hoechst Ag Fusion proteins with immunoglobulin components, their preparation and use
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
GB9509164D0 (en) * 1995-05-05 1995-06-28 Smithkline Beecham Plc Novel compounds
EP0826045A1 (en) * 1995-05-08 1998-03-04 Chiron Corporation Nucleic acids for treating obesity

Also Published As

Publication number Publication date
CA2224646A1 (en) 1997-01-03
WO1997000319A2 (en) 1997-01-03
AU6011096A (en) 1997-01-15
WO1997000319A3 (en) 1997-04-10
JPH11507547A (en) 1999-07-06
EP0832219A2 (en) 1998-04-01

Similar Documents

Publication Publication Date Title
GB9511935D0 (en) Novel compound
GB9507203D0 (en) Novel compounds
GB9509164D0 (en) Novel compounds
GB9503717D0 (en) Novel compounds
GB9518417D0 (en) Novel compound
GB9503112D0 (en) Novel compound
GB9511934D0 (en) Novel compound
GB9511933D0 (en) Novel compound
GB9500399D0 (en) Novel compound
GB9502297D0 (en) Novel compound
GB9501157D0 (en) Novel compound
GB9500400D0 (en) Novel compound
GB9511937D0 (en) Novel compound
GB9526538D0 (en) Novel compound
GB9511936D0 (en) Novel compound
GB9500447D0 (en) Compound
GB9504400D0 (en) Novel compounds
GB9510186D0 (en) Novel compounds
GB9502052D0 (en) Novel compounds
GB9503172D0 (en) Novel compounds
GB9503613D0 (en) Novel compounds
GB9503648D0 (en) Novel compounds
GB9502051D0 (en) Novel compounds
GB9500264D0 (en) Novel compounds
GB9504718D0 (en) Novel compounds